NCT06276634 Intermittent Hypoxia in Persons With Multiple Sclerosis
| NCT ID | NCT06276634 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shirley Ryan AbilityLab |
| Condition | Multiple Sclerosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 21 participants |
| Start Date | 2024-04-30 |
| Primary Completion | 2025-11-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 21 participants in total. It began in 2024-04-30 with a primary completion date of 2025-11-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are similar to breathing the air on a tall mountain, for less than 1 minute at a time. Previous studies have shown that AIH is a safe and effective way to increase strength in persons with MS. Here the investigators aim to look at brain activation and ankle strength before and after AIH to gain a better understanding of how the AIH may improve strength in those persons with MS.
Eligibility Criteria
Inclusion Criteria: * Diagnoses of relapsing form of MS (including relapsing-remitting MS and secondary-progressive MS) * Expanded Disability Status Scale (EDSS) score of at least 3 and no more than 6.5 * Motor Functional System Scale (FSS) between 2-4 * Relapse free for at least 1 year * Age ≥ 18 years and ≤ 75 years * Safe to be scanned based on MRI questionnaire * Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening Exclusion Criteria: * Active contrast-enhancing MS lesions, or diffusion positive lesions suggestive of acute cerebrovascular disease on baseline MRI scan * Uncontrolled hypertension (Systolic between 85 and 140, diastolic between 90 and 55) * History of epilepsy * Chronic obstructive pulmonary disease * Uncontrolled Sleep apnea * Pregnancy
Contact & Investigator
Milap Sandhu, Pt, PhD
PRINCIPAL INVESTIGATOR
Shirley Ryan AbilityLab
Frequently Asked Questions
Who can join the NCT06276634 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06276634 currently recruiting?
Yes, NCT06276634 is actively recruiting participants. Contact the research team at abarry@sralab.org for enrollment information.
Where is the NCT06276634 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06276634 clinical trial?
NCT06276634 is sponsored by Shirley Ryan AbilityLab. The principal investigator is Milap Sandhu, Pt, PhD at Shirley Ryan AbilityLab. The trial plans to enroll 21 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.